Bristol-myers Squibb Stock Fair Value Calculation – Daiwa Capital Markets Initiates Coverage on Bristol-Myers Squibb
June 30, 2023
🌥️Trending News
BRISTOL-MYERS ($NYSE:BMY): Daiwa Capital Markets has initiated coverage on the shares of Bristol-Myers Squibb in a research note to investors on Wednesday morning. Bristol-Myers Squibb is a global biopharmaceutical company that discovers, develops, and markets a wide range of products in the areas of pharmaceuticals, biologics, consumer health, and medical devices. The company has a long history of discovering and developing innovative products that have improved the lives of millions of people around the world. Their portfolio includes treatments for a variety of conditions, including cancer, HIV/AIDS, diabetes, rheumatoid arthritis, Crohn’s disease, and heart disease.
In addition to their pharmaceuticals and biologics, Bristol-Myers Squibb also produces consumer health products such as vitamins and over-the-counter medications. The company also produces medical devices such as infusion pumps and insulin delivery systems. Daiwa Capital Markets has initiated coverage on Bristol-Myers Squibb with the expectation that the company will continue to innovate and lead in the pharmaceuticals and biologics industry.
Market Price
At the open, BRISTOL-MYERS SQUIBB stock opened at $63.8, while it closed at $64.0, a slight 0.1% decline from its prior closing price of $64.1. Despite the minor drop in price, Daiwa Capital Markets believes that Bristol-Myers Squibb is well-positioned for growth over the coming years. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Bristol-myers Squibb. More…
| Total Revenues | Net Income | Net Margin |
| 45.85k | 7.31k | 17.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bristol-myers Squibb. More…
| Operations | Investing | Financing |
| 12.22k | -1.37k | -14.36k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bristol-myers Squibb. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 94.28k | 62.4k | 15.15 |
Key Ratios Snapshot
Some of the financial key ratios for Bristol-myers Squibb are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 13.9% | 21.2% | 21.8% |
| FCF Margin | ROE | ROA |
| 24.2% | 19.9% | 6.6% |
Analysis – Bristol-myers Squibb Stock Fair Value Calculation
At GoodWhale, we conducted an analysis of BRISTOL-MYERS SQUIBB‘s wellbeing and found that its intrinsic value, calculated by our proprietary Valuation Line, is around $70.7. This figure is approximately 9.5% higher than the current price of BRISTOL-MYERS SQUIBB stock, which is traded at $64.0. This suggests that BRISTOL-MYERS SQUIBB is currently undervalued and could represent a good long-term investment opportunity. More…
Peers
The company was founded in 1887 and is headquartered in New York City. The company’s products are sold in over 100 countries. Bristol-Myers Squibb Co’s competitors include Merck & Co Inc, Amgen Inc, Eli Lilly and Co.
– Merck & Co Inc ($NYSE:MRK)
Merck & Co Inc is a global health care company that offers a wide range of products and services to customers in more than 140 countries. The company has a market cap of 236.25B as of 2022 and a Return on Equity of 28.84%. Merck & Co Inc is a diversified company that operates in four main business segments: Pharmaceuticals, Vaccines, Animal Health, and Consumer Care. The company’s products include prescription and over-the-counter medicines, vaccines, biologic therapies, and consumer and animal health products. Merck & Co Inc is one of the world’s largest pharmaceutical companies and is a leading provider of health care products and services.
– Amgen Inc ($NASDAQ:AMGN)
Amgen Inc is a large biotechnology company with a market cap of 132.76B as of 2022. The company has a strong return on equity of 460.37%. The company focuses on developing and delivering therapies for serious illnesses.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a pharmaceutical company with a market cap of 312.88B as of 2022. Its return on equity is 45.88%. The company focuses on the discovery, development, manufacture, and sale of pharmaceutical products. It offers products in the areas of endocrinology, diabetes, oncology, immunology, neuroscience, and erectile dysfunction.
Summary
Daiwa Capital Markets has released a new research note on Bristol-Myers Squibb which provides a detailed investing analysis. The report reviews the company’s current financial position, including sales and earnings growth, debt and liquidity levels, cash flow, and return on equity. The report also provides an outlook on the stock, including an assessment of the company’s market dynamics, competitive landscape, and potential risks and opportunities.
In addition, the note provides a comprehensive overview of the company’s financials and a valuation analysis. Ultimately, the note provides investors with an overall assessment of the company’s prospects for long-term value creation.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
